622 related articles for article (PubMed ID: 22875911)
21. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
[TBL] [Abstract][Full Text] [Related]
23. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).
Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y
Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269
[TBL] [Abstract][Full Text] [Related]
25. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
26. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
[TBL] [Abstract][Full Text] [Related]
27. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
[TBL] [Abstract][Full Text] [Related]
28. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood.
Fujimaki S; Funato T; Harigae H; Imaizumi M; Suzuki H; Kaneko Y; Miura Y; Sasaki T
Eur J Haematol; 2000 Apr; 64(4):252-8. PubMed ID: 10776697
[TBL] [Abstract][Full Text] [Related]
29. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
Zhu HH; Zhang XH; Qin YZ; Liu DH; Jiang H; Chen H; Jiang Q; Xu LP; Lu J; Han W; Bao L; Wang Y; Chen YH; Wang JZ; Wang FR; Lai YY; Chai JY; Wang LR; Liu YR; Liu KY; Jiang B; Huang XJ
Blood; 2013 May; 121(20):4056-62. PubMed ID: 23535063
[TBL] [Abstract][Full Text] [Related]
30. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
32. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
33. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ
Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
Tobal K; Yin JA
Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
[TBL] [Abstract][Full Text] [Related]
35. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
[TBL] [Abstract][Full Text] [Related]
36. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR.
Tobal K; Liu Yin JA
Methods Mol Med; 2006; 125():149-61. PubMed ID: 16502583
[TBL] [Abstract][Full Text] [Related]
38. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
39. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
40. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
